ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ Treg cells and induces sustained amelioration of collagen-induced arthritis.

Journal article

OBJECTIVE: To assess the therapeutic potential of anti-CD3 monoclonal antibodies (mAb) for rheumatoid arthritis, using collagen-induced arthritis as an animal model. METHODS: Arthritis was induced in DBA/1 mice by immunization with type II collagen. After disease onset, a single injection of anti-CD3 mAb (20 microg/mouse) was administered, and arthritis severity was monitored over a 10-day period. RESULTS: Anti-CD3 mAb treatment resulted in a sustained reduction in disease activity, which wa...

Expand abstract

Authors: Notley, C; McCann, F; Inglis, J; Williams, R

• Publication status: Published
• Journal: Arthritis and rheumatism
• Volume: 62
• Issue: 1
• Pages: 171-178
• Publication date: 2010-01-01
• DOI: 10.1002/art.25058
• EISSN: 1529-0131
• ISSN: 0004-3591
• Language: English
• Keywords: Animals; Antigens, CD3; Interferon-gamma; Lymph Nodes; Antirheumatic Agents; Cell Proliferation; Antibodies, Monoclonal; CD8-Positive T-Lymphocytes; Interleukin-17; Hindlimb; Mice, Inbred DBA; Cell Count; Arthritis, Experimental; Cells, Cultured; T-Lymphocytes, Regulatory; Joints; Mice; Male